TVM Capital’s second dedicated life sciences fund focused primarily on discovery and development stage investments throughout Europe and the United States. The sector focus remained unchanged from previous investments – albeit with a stronger allocation to late-stage deals - with a strong emphasis on platform technologies that enhance drug discovery, integrated drug discovery, drug delivery and drug development companies. IPOs from this fund have included Addex, Acorda, Sirtris and Jerini. Strategic corporate buyers bought Jerini and Sirtris in 2008.
